Revitope Oncology, Inc., a San Francisco, California-based cancer immunotherapy company, raised $8.5m in funding.
The company intends to use the funds to continue the development of its novel immunotherapy platform for the treatment of solid tumors and hematologic malignancies.
Led by Julie M. Cherrington, Ph.D., president and CEO, Revitope Oncology develops a novel platform based on redirecting viral immunity for the purpose of developing compounds to treat solid tumors and hematologic malignancies.
Based on research initiated in 2010 by Dr. Mark Cobbold at the University of Birmingham in Birmingham, UK, and supported by affiliates of Cancer Research UK and others, a UK subsidiary of the company was launched in 2014 to continue development of the platform, which redirects a viral immune response that already exists in order to treat cancer. Its antibody peptide epitope complex (APEC) platform utilizes tumor-targeting antibodies to selectively deliver viral antigens to cancer cells. Existing, virus-specific T cells then recognize tumor cells as virally infected and kill them.
Revitope plans to deploy the APEC platform to develop multiple compounds for the treatment of solid tumors and hematologic malignancies.
In addition to Cherrington and Andrew Allen, M.D., Ph.D., president and CEO of Gritstone Oncology, Revitope’s board of directors includes Mark Cobbold, M.D., Ph.D.; Peter M. Joost; and Raj Mehta, Ph.D.